AU2001276952A1 - Method of treating the syndrome of coronary heart disease risk factors in humans - Google Patents

Method of treating the syndrome of coronary heart disease risk factors in humans

Info

Publication number
AU2001276952A1
AU2001276952A1 AU2001276952A AU7695201A AU2001276952A1 AU 2001276952 A1 AU2001276952 A1 AU 2001276952A1 AU 2001276952 A AU2001276952 A AU 2001276952A AU 7695201 A AU7695201 A AU 7695201A AU 2001276952 A1 AU2001276952 A1 AU 2001276952A1
Authority
AU
Australia
Prior art keywords
syndrome
humans
treating
heart disease
risk factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001276952A
Inventor
Anton H. Clement
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CPD LLC
Original Assignee
CPD LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CPD LLC filed Critical CPD LLC
Publication of AU2001276952A1 publication Critical patent/AU2001276952A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AU2001276952A 2000-08-15 2001-07-17 Method of treating the syndrome of coronary heart disease risk factors in humans Abandoned AU2001276952A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/639,061 2000-08-15
US09/639,061 US6262062B1 (en) 2000-08-15 2000-08-15 Method of treating the syndrome of coronary heart disease risk factors in humans
PCT/US2001/022467 WO2002013801A2 (en) 2000-08-15 2001-07-17 Method of treating the syndrome of coronary heart disease risk factors in humans

Publications (1)

Publication Number Publication Date
AU2001276952A1 true AU2001276952A1 (en) 2002-02-25

Family

ID=24562565

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001276952A Abandoned AU2001276952A1 (en) 2000-08-15 2001-07-17 Method of treating the syndrome of coronary heart disease risk factors in humans

Country Status (4)

Country Link
US (1) US6262062B1 (en)
EP (1) EP1357907A2 (en)
AU (1) AU2001276952A1 (en)
WO (1) WO2002013801A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6498702B1 (en) * 1999-02-22 2002-12-24 Hitachi, Ltd. Magnetic head supporting apparatus having thermally insulated read/write IC mounted on arm portions thereof
US20040097996A1 (en) 1999-10-05 2004-05-20 Omnisonics Medical Technologies, Inc. Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode
US20050096669A1 (en) * 1999-10-05 2005-05-05 Omnisonics Medical Technologies, Inc. Apparatus and method for an ultrasonic medical device to treat coronary thrombus bearing lesions
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
JP2005531557A (en) * 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Use of effective compounds as selective opiate receptor modulators
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
DE10259245A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivatives of asimadolin with covalently bound acids
US7314880B2 (en) * 2003-01-02 2008-01-01 Mount Cook Biosciences, Inc. Cardioprotective delta opioid receptor agonists and methods of using same
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7862833B2 (en) * 2003-12-31 2011-01-04 Cima Labs, Inc. Effervescent oral opiate dosage forms and methods of administering opiates
NZ548216A (en) * 2003-12-31 2010-02-26 Cima Labs Inc Generally linear effervescent oral fentanyl dosage form and methods of administering
US7794414B2 (en) 2004-02-09 2010-09-14 Emigrant Bank, N.A. Apparatus and method for an ultrasonic medical device operating in torsional and transverse modes
ES2507098T3 (en) 2005-11-07 2014-10-14 Indiana University Research And Technology Corporation Glucagon analogs showing physiological solubility and stability
CA2666846C (en) * 2006-10-20 2018-04-10 Cpd, Llc Method of restoring the incretin effect
EP2124974B1 (en) 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5416085B2 (en) 2007-03-30 2014-02-12 ティオガ ファーマシューティカルズ インコーポレイテッド Kappa-opiate agonists for the treatment of diarrhea and alternating irritable bowel syndrome
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
JP5771005B2 (en) 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon antagonist and compound showing GLP-1 agonist activity
US8546327B2 (en) 2008-06-17 2013-10-01 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5753779B2 (en) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analogs with improved solubility and stability in buffers at physiological pH
PL2300035T3 (en) 2008-06-17 2016-04-29 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
KR20110110174A (en) 2008-12-19 2011-10-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Amide based glucagon superfamily peptide prodrugs
MX2011013625A (en) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds.
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
RU2012136450A (en) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн CONJUGATES GLUCAGON ANTAGONIST - GIP AGONIST AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY
KR20130111923A (en) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
CA2797095A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
MA34885B1 (en) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp GLUCAGON ANALOGS HAVING A GIP RECEPTOR ACTIVITY
CN103748109A (en) 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 Glucagon/glp-1 receptor co-agonists
LT2723367T (en) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2013074910A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
RU2015101697A (en) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн GLUCAGON ANALOGUES WITH GIP RECEPTOR ACTIVITY
WO2016073615A1 (en) 2014-11-07 2016-05-12 Regents Of The University Of Minnesota Salts and compositions useful for treating disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055175A (en) 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
US4272540A (en) * 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4451470A (en) * 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4511570A (en) 1983-03-28 1985-04-16 Key Pharmaceuticals, Inc. Senile dementia treatment
HU201675B (en) * 1983-08-26 1990-12-28 Ivan Balkanyi Process for producing oral pharmaceutical compositions with unappetizing effect
US4478840A (en) * 1983-10-11 1984-10-23 E. I. Du Pont De Nemours And Company Appetite suppressing compositions and methods
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US5356900A (en) 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
US5468755A (en) 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4880813A (en) 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US4877791A (en) 1988-11-01 1989-10-31 Baker Cummins Pharmaceuticals, Inc. Method of treatment for interestitial cystitis
US4857533A (en) 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US4994466A (en) 1990-06-14 1991-02-19 Baker Cummins Pharmaceuticals, Inc. Method of treatment for multiple sclerosis
DE4136215A1 (en) * 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De USE OF OPIATE ANTAGONISTS FOR TREATING ENDOGENIC HYPERINSULINAEMIA
US5626860A (en) 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US6026817A (en) 1996-11-14 2000-02-22 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5727570A (en) 1996-11-14 1998-03-17 Clemens; Anton H. Method of treating hyperlipidemia in humans

Also Published As

Publication number Publication date
WO2002013801A3 (en) 2003-08-21
WO2002013801A2 (en) 2002-02-21
EP1357907A2 (en) 2003-11-05
US6262062B1 (en) 2001-07-17

Similar Documents

Publication Publication Date Title
AU2001276952A1 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
AU2001249881A1 (en) Method of treating the heart
ZA983451B (en) Substituted imidazoles useful in the treatment of inflammatory diseases.
EP1416961A4 (en) Composition and method for the treatment of disease
AU8880701A (en) Cardiac arrhythmia treatment methods
AU2002227234A1 (en) Circulation set for temperature-controlled catheter and method of using the same
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
AU8023200A (en) Pulmonary vein stent and method for use
AU2002231034A1 (en) Non-invasive method for treating postural instability
EP1432310A4 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
EP1018965A4 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
AU2003214725A1 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
AU2002367023A1 (en) Compositions and methods for treating heart failure
AU2002220266A1 (en) Methods for the identification and the treatment of cardiovascular disease
AU2002365057A1 (en) Compositions and methods for treating heart failure
AU2003216524A1 (en) Methods for inducing vascular remodeling and related methods for treating diseased vascular structures
HUP0200738A3 (en) Method of the treatment of incontinence
AU5262200A (en) Arrangement in ventilatory treatment of the lungs
ZA200203435B (en) Method and compositions for treating pulmonary diseases.
AU6726700A (en) Method of treating 1,1,1,3,3-pentafluoropropane
AU2001275959A1 (en) Method of treating the syndrome of type 2 diabetes in humans
IL148822A0 (en) Wood treatment
AU2002315139A1 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease